China based WuXi Biologics has entered into a collaboration with Adagene Inc. to support supply of Adagene's products for clinical trials under Investigational New Drug (IND) applications in both China and United States.

Adagene is building a global biotech company with an internal pipeline of antibody therapeutics focused on difficult antigens, and therapeutic candidates with enhanced biophysical properties.

The strategic collaboration with WuXi Biologics will enable Adagene to focus on the core competency in the discovery of novel antibody therapeutics and by leveraging the process development and manufacturing capabilities of WuXi Biologics will accelerate Adagene's next wave of innovative products into the clinic.